Key takeaways:
Biopharmaceutical R&D organizations are making significant bets on artificial intelligence (AI). Recent breakthroughs have demonstrated the technology’s transformative potential in accelerating drug discovery.1 With R&D executives remaining bullish about AI’s impact(4)2 and industry investment projected to reach between $5.65 billion to $25 billion by 2030,3 companies are racing to harness this technology to enhance insight generation and improve automation of laboratory work and data flows.
However, much of the recent innovation has been driven by models widely available across the industry. To truly drive a competitive advantage with AI, companies will need to utilize proprietary research data to train their own models, or fine-tune existing models. However, research data notoriously lacks the proper metadata context—ranging from experimental design, assay conditions, and other critical background—to effectively train these models for use in drug discovery. Companies that fail to address these foundational data and metadata challenges could potentially struggle to capitalize on AI’s promise. Strategic industry efforts recognize that high-quality, contextualized, cross-collaboration research data is essential to fuel the next generation of AI-driven discovery.
Here’s an overview as to why contextualized, cross-collaboration research tools will give research companies the greatest competitive advantage.
Why metadata is the real competitive differentiator in AI-driven R&D
Proper metadata capture helps retain this important context and extend the value of research data for both data interoperability and AI usage. Additionally, the rich annotation of research data enables companies to achieve the “laboratory in the loop” effect, which ultimately connects lab experimental results back to the models that predicted the outcome of those experiments so that the technology can learn and get better over time.
In today’s laboratory environment, the failure to capture broad metadata, even beyond what is necessary to complete the experiment at hand, is prevalent. Scientists are often not incentivized to invest the time to capture the necessary context that makes that data useful beyond its initial purpose. And for good reason, it is often very laborious to do so . Solving this friction of metadata capture for scientists will be an important step in making research data “AI-ready.”
In a similar manner, Deloitte and Amazon Web Services (AWS) are fueling the next generation of AI-driven discovery with our Lab of the Future solution suite of cloud-based accelerators that properly and automatically capture, structure, and link metadata to experimental results, all to help scientific organizations realize meaningful returns.
Metadata is also essential for the next generation of pharmaceutical R&D workflows
It is becoming clear that agentic systems can autonomously solve more complex automation problems when provided with properly contextualized data. Therefore, scientific workflows combined with autonomous lab systems become a force multiplier for productivity enhancements at an organizational scale. Without the proper metadata, however, these systems and laboratory automations do not have sufficient context to elevate decision-making and problem-solving from simple, rule-based processing to a cognitive, agentic workflow capable of dealing with unexpected circumstances.
Metadata encompasses all information surrounding experimental design, conditions, and results, giving researchers the contextual framework needed to accurately interpret observations. The scope of metadata is vast and dynamic, with its structure and necessary elements changing across experiments and over time.
Research programs often build upon prior work and knowledge that informs future experimental design. Researchers rely on the associated metadata that encompasses study intent, protocol nuances, and the human decisions during data collection and analysis. Because of this complexity, formalizing the capture of metadata is crucial for maximizing and preserving the value of research data, even as what counts as “necessary” metadata evolves alongside scientific progress.
As organizations strive to create FAIR (Findable, Accessible, Interoperable, and Reusable) research data , a key challenge lies in managing metadata effectively across three interconnected dimensions.
Capture
Metadata capture frequently relies on manual entry across siloed tools, fragmented workflows, and inconsistent ontologies, making it difficult for scientists to document contextual metadata. As a result, critical details are often captured as free text, recorded inconsistently, entered manually (often with errors), or omitted altogether. When essential context is not embedded naturally within the scientific workflow, experimental data quickly loses interpretability and reusability.
Standardization
Without shared standards, metadata becomes fragmented as teams and systems use their own conventions and terminology. Cross-study analysis becomes nearly impossible because data fields from different labs or systems can’t be directly compared, and manual mapping is slow and error-prone. This lack of alignment keeps valuable data siloed and unable to be referenced or integrated into future research.
Integration
Research metadata resides across a fragmented landscape of legacy and modern systems, each responsible for distinct domains including projects, experiments, samples, and instruments. The absence of seamless integration across these hierarchical metadata domains creates barriers to reconstructing the full experiment context and lineage. This limits organizational visibility across programs and modalities, undermines end-to-end traceability, and impedes the realization of enterprise-scale analytics, AI, and innovation.
These challenges matter because without systemic change, persistent metadata gaps perpetuate inefficiency, limit reusability, and erode the long-term value of scientific research.
The laboratory of the future will require solutions that automate the collection of metadata throughout all phrases of research and improve the quality of experimental records. The most useful automated workflows will do three things:
Figure 1: Metadata collection and standardization can be automated throughout the experimental process. This in turn will empower data-driven research processes and preserve the value of organizational R&D data.
This vision represents a fundamental change in ways of working in R&D. The technology that will enable this transformation will allow researchers to generate and consume scientific data through natural language queries, intelligent agents, and self-documenting systems. By automating metadata capture and management across every phase of research, these solutions free up scientists capacity to focus on discovery while improving data quality, findability, and reusability. This approach will empower data-driven and efficient research practices that will generate more transparent and informed decision-making.
Sign up to receive part 2 of this metadata series before it’s published. We’ll explore the Deloitte and AWS technology that’s solving the challenges of metadata management and turning the vision of the lab of the future into a reality.
Endnotes
1. OpenAI, “GPT-5 lowers the cost of cell-free protein synthesis,” February 5, 2026; Insilico Medicine, “Insilico Medicine announces 2025 annual results, redefining value delivery in AI-powered drug discovery,” press release, March 29, 2026; Apheris, “AI Structural Biology (AISB) Network,” accessed May 2026.
2. Pete Lyons et al., 2026 Life Sciences Outlook, Deloitte Insights, December 9, 2025.
3. Knowledge Sourcing Intelligence (KSI), “Artificial intelligence (AI) in life sciences market expected to reach USD 5.650 billion by 2030,” press release, December 26, 2025; Coherent Market Insights, Artificial intelligence in life science market size and share analysis – Growth trends and forecasts (2026–2033), March 30, 2026; Chris Bourne, “Pharma at an inflection point: Where capital, technology and geography are reshaping drug development between 2024 and 2025,” FounderNest, November 22, 2025.